Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)

Autor: Sophie Susen, Hervé Chambost, Annie Harroche, Valérie Chamouard, Bénédicte Wibaut, Pierre Albaladejo, Yves Gruel, Antoine Rauch, Emmanuel de Maistre, Claude Negrier, Stéphanie Roullet, Anne Godier, Jenny Goudemand, Dominique Lasne, Pierre Fontana
Přispěvatelé: Université de Lille, Département d'hématologie - Hémostase, Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Innovations thérapeutiques en hémostase (IThEM - U1140), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de pédiatrie, d'hématologie et d'oncologie [Hôpital de La Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Université de Bordeaux (UB), Hôpitaux Universitaires de Genève (HUG), Université de Genève (UNIGE), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Université Grenoble Alpes (COMUE) (UGA), Département d'anesthésie–réanimation, CHU Grenoble-Hôpital Michallon, Université de Genève = University of Geneva (UNIGE), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
Rok vydání: 2019
Předmět:
Zdroj: Haemophilia
Haemophilia, Wiley, 2019, ⟨10.1111/hae.13817⟩
Haemophilia, 2019, ⟨10.1111/hae.13817⟩
ISSN: 1365-2516
1351-8216
DOI: 10.1111/hae.13817
Popis: International audience; Introduction Emicizumab (Hemlibra (R)) recently became available and requires an adaptation for managing bleeding, suspected bleeding and emergency or scheduled invasive procedures in haemophilia A patients with inhibitor. This implicates a multidisciplinary approach and redaction of recommendations for care that must be regularly adapted to the available data. Aim The following text aims to provide a guide for the management of people with haemophilia A with inhibitor treated with emicizumab in case of bleeding or invasives procedures. Methods The French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia (CRH), in collaboration with the French Working Group on Perioperative Haemostasis (GIHP) have been working together to make proposals for the management of these situations. Results Haemostatic treatment and other medications should be given stepwise, according to the severity and location of the bleeding or the risk of bleeding of the procedure as well as the haemostatic response obtained at each step in order to ensure an optimal benefit/risk ratio. Conclusion The lack of data means that it is only possible to issue proposals rather than recommendations.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje